



PATENT

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 02-325-A (400/047) )

In the Application of:

Pavco et al.

Serial No.: 10/712,633

Filing Date: November 13, 2003

For: Nucleic Acid Based Modulation of Female  
Reproductive Diseases and Conditions

Examiner:

Group Art Unit: 1635

Confirmation No. 6362

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

**TRANSMITTAL LETTER**

In regard to the above identified application:

1. We are transmitting herewith the attached papers for the above identified new patent application:

- Second Supplemental Information Disclosure Statement;
- Second Supplemental Information Disclosure Statement (IDS) PTO-1449 Form;
- Copies of IDS Citations for S/N 10/712,633 (Total 19 foreign patents and 16 other documents); and
- Return Receipt Postcard.

2. With respect to additional fees, no additional fee is required.

3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.

4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria Virginia 22313-1450 on July 12 2005.

By :

Anita J. Terpstra  
Reg. No. 47,132



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. 02-325-A (400/047) )

In the Application of: )  
Pavco et al. )  
Serial No.: 10/712,633 )  
Filing Date: November 13, 2003 )  
For: Nucleic Acid Based Modulation of Female )  
Reproductive Diseases and Conditions )  
Examiner:  
Group Art Unit: 1635  
Confirmation No. 6362

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Second Supplemental Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the cited references are enclosed. These references are also listed on the enclosed PTO Form 1449.

The Office has amended the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. patent applications. See 69 Fed. Reg. 56481. In accordance with this amendment, cited U.S. patents and U.S. patent application publications are not enclosed.

This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief is in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

Respectfully submitted,  
**McDonnell Boehnen Hulbert & Berghoff LLP**

Date: July 12 2005

By:

Anita J. Terpstra  
Reg. No. 47,132

McDonnell Boehnen Hulbert & Berghoff LLP  
300 South Wacker Drive, 32<sup>nd</sup> Floor  
Chicago, IL 60606  
Telephone: 312-913-0001  
Facsimile: 312-913-0002

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No. Serial No.

02-325-A (400/047) 10/712,633



SECOND SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant:

Pavco et al.

Filing Date: Group:

November 13, 2003 1635

**U.S. PATENT APPLICATION DOCUMENTS**

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
	*	US 2003/0190635	10/2003	McSwiggen et al.			
	*	US 2003/0206887	11/2003	Morrissey et al.			

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	*	5,814,620	09/28/98	Robinson et al.			
	*	5,998,203	12/1999	Matulic-Adamic et al.			
	*	6,506,559	01/14/03	Fire et al.			

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	1.	2,359,180	03/08/00	CA (Kreutzer et al.)				
	2.	1325955	07/09/03	EP (Klipfel-Giese et al.)				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			
(Use several sheets if necessary)			
<b>Applicant:</b> Pavco et al.			
<b>Filing Date:</b> November 13, 2003		<b>Group:</b> 1635	

	33.	08208687	08/1996	JP (Hotoda et al.)				
	3.	90/14090	11/29/90	WO (Gillespie et al.)				
	4.	94/01550	01/20/94	WO (Agrawal et al.)				
	5.	97/21808	06/19/97	WO (Robinson)				
	6.	99/49029	09/30/99	WO (Graham et al.)				
	7.	00/49035	08/24/00	WO (Sheen et al.)				
	8.	01/097850	12/27/01	WO (Siemeister et al.)				
	9.	01/96584	12/20/01	WO (Mushegian et al.)				
	10.	02/07747	01/31/02	WO (King)				
	11.	02/10378	02/07/02	WO (Cowser et al.)				
	12.	02/22636	03/21/02	WO (Bennett et al.)				
	13.	03/068797	08/21/03	WO (Rossi et al.)				
	14.	03/070910	08/28/03	WO (McSwiggen et al.)				
	15.	03/080638	10/02/03	WO (Lacasse et al.)				
	16.	04/009769	01/29/04	WO (Tolentino et al.)				
	17.	04/043977	05/27/04	WO (Prakush et al.)				
	18.	04/072261	08/26/04	WO (Li et al.)				

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			
(Use several sheets if necessary)			
<b>Applicant:</b> Pavco et al.			
<b>Filing Date:</b> November 13, 2003		<b>Group:</b> 1635	

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

19.	Anderson et al., "Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance," <i>Oligonucleotides</i> , 13:303-312 (2003)
34.	Bayard et al., "Increased stability and antiviral activity of 2'-O-phosphoglyceryl derivatives of (2'-5')oligo(adenylate)," <i>Eur. J. Biochem.</i> , 142(29):291-298 (1984)
20.	Elbashir et al., "Functional Anatomy of siRNAs for Mediating Efficient RNAi in <i>Drosophila Melanogaster</i> Embryo Lysate," <i>The EMBO Journal</i> 20:6877-6888 (2001)
21.	Futami et al., "Induction of apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2," <i>Nucleic Acids Research Supplement</i> , 251-252 (2002)
22.	International Search Report for PCT/US02/17674 mailed November 12, 2002
23.	International Search Report for PCT/US03/05022 mailed January 6, 2005
24.	International Search Report for PCT/US03/05028 mailed October 17, 2003
25.	International Search Report for PCT/US03/05346 mailed October 17, 2003
26.	International Search Report for PCT/US2004/016390 mailed March 31, 2005
27.	International Search Report for PCT/US2004/030488 mailed January 12, 2005
28.	Leirdal et al., "Gene silencing in mammalian cells by preformed small RNA duplexes," <i>Biochemical and Biophysical Research Communications</i> , 295, 744-748 (2002)
29.	Lin et al., "A Novel mRNA-cRNA Interference Phenomenon for Silencing bcl-2 Expression in Human LNCaP Cells," <i>Biochemical and Biophysical Research Communications</i> , 281, 639-644 (2001)
35.	Lu et al., "Tumor Inhibition By RNAi-Mediated VEGF and VEGFR2 Down Regulation in Xenograft Models," <i>Cancer Gene Therapy</i> , 10, Suppl. 1, S4-S5 (2003)
30.	Parry et al. 1999. "Bioactivity of anti-angiogenic ribozymes targeting <i>Flt-1</i> and <i>KDR</i> mRNA," <i>Nucleic Acid Res.</i> 27:2569-77.
31.	Tuschl et al., "Small Interfering RNAs: A Revolutionary Tool for Analysis of Gene Function and Gene Therapy," <i>Molecular Interventions</i> , 295, 3, 158-167 (2002)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-325-A (400/047)	Serial No. 10/712,633
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			
(Use several sheets if necessary)			
<b>Applicant:</b> Pavco et al.			
<b>Filing Date:</b> November 13, 2003		<b>Group:</b> 1635	

	32.	Tuschl, "RNA Interference and Small Interfering RNAs," <u>Chembiochem</u> 2:239-245 (2001)
--	-----	--

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.